News
We are a world-leading cancer research institute, a charity, and a member institution of the University of London. Public donations and clinical partnerships are helping us to make the discoveries ...
Researchers at The Institute of Cancer Research, London, have uncovered a hidden weakness in some breast cancer tumours that could lead to smarter treatment decisions.
Amy McGeoch earned her Bachelor's degree in biochemistry from the University of Leeds. She plans to investigate the involvement of cyclin-dependent kinase complexes in non-canonical pathways such as ...
A new genetically engineered virus has delivered a one-two punch against advanced cancers in initial findings from a phase I trial. Researchers found that RP2 – a modified version of the herpes ...
A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown. A team from The Institute of Cancer Research, ...
Image: DNA sequence. Credit: The Institute of Cancer Research, London. A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for one ...
The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...
Twenty years ago today, the International Genome Sequencing Consortium published the first detailed analysis of the human genome. The paper appeared online in Nature on 15 February 2001, followed by a ...
The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned. According to a new modelling study, published in the journal ...
Scientists have worked out how a protective element of our DNA helps prevent an abnormal genetic event that can lead to cells becoming cancerous. They have shown exactly how telomeres – the protective ...
The latest major breakthrough in cancer is a drug called capivasertib, which has shown ‘remarkable’ results against advanced breast cancer in its first phase III trial. Results released at the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results